Goldman Sachs
ESPR

Goldman Sachs’s Esperion Therapeutics ESPR Stock Holding History

Goldman Sachs’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-30,000
Closed -$946K – 5271
2020
Q1 		$946K Buy
+30,000
New +$1.58M ﹤0.01% 3803
2019
Q1 		– Sell
-5,000
Closed -$230K – 5214
2018
Q4 		$230K Hold
5,000
– – ﹤0.01% 4760
2018
Q3 		$222K Hold
5,000
– – ﹤0.01% 4869
2018
Q2 		$196K Buy
+5,000
New +$253K ﹤0.01% 4999
2018
Q1 		– Sell
-6,300
Closed -$415K – 6007
2017
Q4 		$415K Sell
6,300
-9,700
-61% -$522K ﹤0.01% 4975
2017
Q3 		$802K Sell
16,000
-15,700
-50% -$757K ﹤0.01% 4763
2017
Q2 		$1.47M Sell
31,700
-3,600
-10% -$132K ﹤0.01% 4106
2017
Q1 		$1.25M Buy
35,300
+20,800
+143% +$476K ﹤0.01% 4189
2016
Q4 		$182K Buy
14,500
+4,500
+45% +$53.6K ﹤0.01% 5830
2016
Q3 		$139K Buy
10,000
+300
+3% +$3.4K ﹤0.01% 6058
2016
Q2 		$96K Sell
9,700
-33,200
-77% -$550K ﹤0.01% 6148
2016
Q1 		$725K Sell
42,900
-8,000
-16% -$129K ﹤0.01% 4374
2015
Q4 		$1.13M Buy
50,900
+16,100
+46% +$406K ﹤0.01% 4174
2015
Q3 		$821K Sell
34,800
-180,600
-84% -$11.3M ﹤0.01% 4669
2015
Q2 		$17.6M Buy
215,400
+215,200
+107,600% +$21.1M 0.01% 1889
2015
Q1 		$19K Buy
+200
New +$12.9K ﹤0.01% 6904

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Goldman Sachs's ESPR Position: Q2 2026 in Review

Goldman Sachs increased its Esperion Therapeutics (ESPR) stake by 331% in Q2 2026, buying an estimated $22.3M and bringing the position to 10,380,646 shares worth $32.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2175.

Goldman Sachs first reported a position in ESPR in Q3 2013 and has held it in 49 quarters since. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Goldman Sachs held 10,380,646 shares of Esperion Therapeutics worth $32.8M as of Q2 2026.
  • Goldman Sachs bought 7,970,192 Esperion Therapeutics shares in Q2 2026, an estimated $22.3M.
  • Esperion Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2175 holding.
  • Goldman Sachs first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 49 quarters since.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.